ArticleInfectious agents and cancer2013
Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: a population-based study.
Article in Infectious agents and cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies.International journal of public health · 2023Pooled it
- Pooled it
- Porphyrin-based MOFs for Gene Delivery in Cancer Therapy: Recent Advances and Progress.Current pharmaceutical design · 2026Review
- The Fundamental Place of Pap Test in Iran, Does Primary HPV-Genotyping Seem Cost-Effective in Replace? A Cohort Study.International journal of preventive medicine · 2025Article
- High-risk HPV serotype distribution in cervical cancer: comparative analysis of detection in cervicovaginal secretions and tissue DNA extraction.Ecancermedicalscience · 2025Article
- High-risk human papillomavirus infection and cervical cytopathology: relationship with cervical nitric oxide levels.Virology journal · 2024Article
- Survival rate of cervical cancer: a five year review at a Major Teaching Hospital in Ghana, West Africa.Ecancermedicalscience · 2024Article
- TIME Is Ticking for Cervical Cancer.Biology · 2023Review
- Design and Immunological Validation ofFrontiers in immunology · 2021Article
- Oral HPV16 Prevalence in Oral Potentially Malignant Disorders and Oral Cavity Cancers.Biomolecules · 2020Article
- Achieving high uptake of human papillomavirus vaccination in Malaysia through school-based vaccination programme.BMC public health · 2018Article
- Cancer incidence in the East Azerbaijan province of Iran in 2015-2016: results of a population-based cancer registry.BMC public health · 2018Article
- The prevalence and genotyping of human papillomavirus in patients with oral tumors in health centers and clinics of Mazandaran in Iran.Virusdisease · 2018Article
- Assessment of Preventive Behavior for Cervical Cancer with the Health Belief ModelAsian Pacific journal of cancer prevention : APJCP · 2018Article
- HPV infection and P16 expression in oral and oropharyngeal cancer in Kazakhstan.Infectious agents and cancer · 2018Article
- Human Papilloma Virus Genotype Distribution in Cervical lesions in Zanjan, IranAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Evaluating Cervicovaginal Infections and Cervical Cancer in Women with Low Socioeconomic Levels.Iranian journal of public health · 2017Article
- Relative frequency of human papillomavirus genotypes and related sociodemographic characteristics in women referred to a general hospital in Tehran, 2014-2015: A cross-sectional study.International journal of reproductive biomedicine · 2017Article
- Association of High Risk Human Papillomavirus and Breast cancer: A UK based Study.Scientific reports · 2017Article
- Cervical Cancer and Genital Infections: Assessment of Performance and Validation in Human Papillomavirus Genotyping Assays in Iran, its Neighbouring Countries and Persian Gulf Area.Iranian journal of pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the greater cause of cancer death in women in many developing countries. Persistent infection with human papilloma virus (HPV), primarily high risk types 16 and 18, is recognized as a causal and essential factor for the development of cervical cancer. We aimed to determine the distribution of high-risk HPV genotypes in archival biopsies with cervical carcinoma in patients from Mazandaran Province, Northern Iran.
methodsA total of 98 paraffin-embedded cervical samples consisted of 63 Squamous Cell Carcinomas (SCC), 4 Adenocarcinomas, 19 Cervical Interaepithelial Neoplasia grade I (CIN-I), 4 CIN-II and 8 CIN-III diagnosed during 2009-2011, were selected to perform high risk HPV genotyping using AmpliSens(R) HPV HCR DNA genotyping kit. The prevalence of HPV infections was assessed in low and high grade cervical lesions by age.
resultsOf the 98 cervical samples analysed by DNA PCR, 78 (79.59%) were positive for HPV DNA. HPV was detected in the 52 of SCC, 4 of Adenocarcinomas, 14 of CIN-I, 4 of CIN-II, and 4 of CIN-III for HPV. From the 78 HPV positive samples, 23 (29.5%) samples were positive for HPV type 16, 32 (41%) were positive for HPV 18, 19 (24.4%) were positive for HPV 45, and 4 (5.1%) of cervical specimens were positive for HPV 39.
conclusionsThis study provides valuable baseline data for future assessment of the impact of current prophylactic vaccination programs that is protective against the two most common oncogenic types of HPV found in cervical cancer, HPV-16 and HPV-18, but not against other high-risk mucosal HPVs, 39 and 45, reported in this population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.